---
title: Ascendiacdmo vs Delpharm
slug_a: ascendiacdmo
slug_b: delpharm
site: cdmo
review_signal_gate: closed
canonical_path: /compare/ascendiacdmo/delpharm
generated_by: BioBM Editorial AI
---

# Ascendiacdmo vs Delpharm

This comparison is auto-generated by BioBM Editorial AI and intended as an evidence-oriented side-by-side reference.

## Company A

Ascendiacdmo (ascendiacdmo) is listed for cdmo. Ascendia is a specialty CDMO offering formulation development, analytical services, and cGMP manufacturing for small molecules, biologics, and gene delivery therapies, with proprietary nanotechnologies for solubility and bioavailability enhancement.

Services: 11. Modalities: 3. Indications: 0. Locations: 1. Certifications: 0. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in services (11).

Review summary: Review summary withheld until site-level review gate opens.

## Company B

Delpharm (delpharm) is listed for cdmo. Top-5 global CDMO with 18 production sites across Europe and North America, specializing in solid, semi-solid, non-sterile and sterile liquid dosage forms including prefilled syringes, nasal sprays, and injectables; capacity to produce over 300 million units annually.

Services: 14. Modalities: 2. Indications: 0. Locations: 36. Certifications: 0. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in locations (36).

Review summary: Review summary withheld until site-level review gate opens.